MIM
INBX

MetLife Investment Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

MetLife Investment Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,194
Closed -$636K – 2964
2024
Q1 		$636K Hold
18,194
– – ﹤0.01% 1549
2023
Q4 		$691K Hold
18,194
– – 0.01% 1508
2023
Q3 		$334K Hold
18,194
– – ﹤0.01% 1877
2023
Q2 		$472K Buy
18,194
+448
+3% +$10.5K ﹤0.01% 1728
2023
Q1 		$335K Hold
17,746
– – ﹤0.01% 1895
2022
Q4 		$437K Buy
17,746
+519
+3% +$15.3K ﹤0.01% 1727
2022
Q3 		$309K Hold
17,227
– – ﹤0.01% 1997
2022
Q2 		$196K Hold
17,227
– – ﹤0.01% 2335
2022
Q1 		$384K Buy
17,227
+5,704
+50% +$146K ﹤0.01% 1945
2021
Q4 		$503K Hold
11,523
– – ﹤0.01% 1503
2021
Q3 		$384K Hold
11,523
– – ﹤0.01% 1680
2021
Q2 		$317K Buy
+11,523
New +$240K ﹤0.01% 1850
2021
Q1 		– Sell
-3,963
Closed -$131K – 2365
2020
Q4 		$131K Buy
+3,963
New +$105K ﹤0.01% 2181

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MetLife Investment Management's INBX Position: Q2 2024 in Review

MetLife Investment Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 18,194 shares — an estimated $636K sold.

MetLife Investment Management first reported a position in INBX in Q4 2020 and held it in 13 quarters. The position peaked at $691K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • MetLife Investment Management reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • MetLife Investment Management sold 18,194 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $636K.
  • MetLife Investment Management first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • MetLife Investment Management's Inhibrx, Inc. Common Stock position peaked at $691K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.